Gapping up
In reaction to earnings/guidance:
- QDEL +6.8% (issues Q3 guidance well above consensus estimate)
Other news:
- CCXI +63.1% (FDA approves TAVNEOS)
- EFTR +24.1% (presents new positive data for zotatifin in animal models of triple-negative breast cancer)
- RPTX +10% (issues statement regarding inadvertent issuance of abstract)
- VXRT +8.6% (oral COVID-19 vaccine candidate shown to reduce airborne transmission of SARS-CoV-2 in an animal model)
- HGEN +3.6% (enters contract with Clinigen for Lenzilumab Managed Access Program in Europe)
- BW +2.8% (awarded ~$10 mln contract to install ash-handling equipment)
- NXTC +1.6% (reports preclinical data for NC410)
- THO +1.2% (increases dividend)
- TAK +1.2% (receives unanimous recommendation for use of Maribavir from FDA)
- TRNO +1.1% (provides operating update for Q3)
- CI +1.1% (Cigna to divest its Life, Accident And Supplemental Benefits businesses in seven countries to Chubb (CB) for $5.75 bln)
- MOH +1% (to acquire the Medicaid Managed Long Term Care business of AgeWell New York for $110 mln)
Analyst comments:
- UNP +1% (upgraded to Overweight from Neutral at JP Morgan)